Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Jul 14 2025 | U.S. FDA Approves KERENDIA® (finerenone) to Treat Patients With Heart Failure With Left Ventricular Ejection Fraction ≥40% Following Priority Review Industry News In The News Industry Read More Jul 14 2025 | Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension Industry News In The News Industry Read More May 20 2025 | Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM Industry News In The News Industry Read More May 19 2025 | Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study Industry News In The News Industry Read More May 14 2025 | Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal Industry News In The News Industry Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Jul 14 2025 | U.S. FDA Approves KERENDIA® (finerenone) to Treat Patients With Heart Failure With Left Ventricular Ejection Fraction ≥40% Following Priority Review Industry News In The News Industry Read More
Jul 14 2025 | Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension Industry News In The News Industry Read More
May 20 2025 | Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM Industry News In The News Industry Read More
May 19 2025 | Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study Industry News In The News Industry Read More
May 14 2025 | Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal Industry News In The News Industry Read More
